Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On April 17, 2026, she exercised 9,500 stock options at a conversion price of $146.03 per share and acquired an equal number of common shares.
The same day, she sold 9,500 common shares in multiple open-market trades at prices generally around the high-$570s to low-$590s per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she directly holds 40,513 common shares and 17,000 stock options, and also has additional indirect holdings through several family trusts and her spouse.
UNITED THERAPEUTICS director Christopher Patusky exercised stock options and sold shares in a planned transaction. He exercised 1,000 stock options at an exercise price of $101.80 per share, then sold 1,000 common shares at $578.88 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he holds 1,490 common shares directly and 1,100 shares indirectly through a trust.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold shares in a pre-planned transaction. She exercised 9,500 stock options for common stock at an exercise price of $146.03 per share and acquired 9,500 common shares.
On the same date, she sold 9,500 common shares in multiple open-market trades at prices between $573.9595 and $581.3325. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 options expiring on March 17, 2027 or December 31, 2026. After these transactions, she holds 40,513 shares directly, plus additional indirect holdings including 166 shares held by a spouse and 324,443 shares held by family trusts.
UNITED THERAPEUTICS Corp CFO James Edgemond exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and sold 10,000 shares in open-market transactions. The sales occurred on April 16, 2026 in multiple trades at prices reported between $573.9146 and $581.6400 per share.
The filing states that this option exercise and subsequent share sales were made under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. After these transactions, Edgemond directly holds 18,876 shares of Common Stock and 82,500 stock options.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported a planned combination of option exercises and share sales. She exercised stock options for 19,000 shares of common stock at an exercise price of $146.03 per share, then sold 19,075 shares in multiple open-market trades at prices mostly around the high-$570s to low-$580s.
After these direct transactions, she holds 40,513 common shares directly. In addition, indirect holdings include shares held by family trusts and her spouse, with trust and spouse positions ranging from 10,962 to 258,117 shares as of March 13, 2026. The filing notes that the option exercises and resulting sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised stock options and sold shares in a planned transaction. As EVP & General Counsel, he exercised options for 8,300 shares of common stock at an exercise price of $146.03 per share, then sold 8,300 shares in multiple open-market trades at weighted average prices around $574–$578 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. After the trades, he directly owned 45,172 shares of United Therapeutics common stock.
Paul Mahon submitted a Form 144 notice reporting proposed sales of Common Stock, consisting of repeated blocks of 8,300 shares tied to stock option exercises. The filing lists multiple sale dates in Q1–Q2 2026 (examples: 02/05/2026, 03/05/2026, 04/02/2026, 04/16/2026).
The transactions are described as Stock Option Exercise and appear filed through Morgan Stanley Smith Barney LLC as broker. The filing is a regulatory notice of proposed resale activity, not a company operational disclosure.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and acquired the corresponding common shares.
On the same date, she sold 9,500 common shares in multiple open-market transactions, with reported prices including $569.7771, $571.3888 and up to $579.5260 per share, under a pre-arranged Rule 10b5-1 trading plan. Following these trades, she holds 40,513 common shares directly, in addition to indirect holdings by her spouse and in family trusts.
United Therapeutics Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction. He exercised options for 10,000 shares of common stock at an exercise price of $135.42 per share and then sold 10,000 shares in open-market trades at prices ranging from about $569.28 to $580.03. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. After the sales, he directly holds 18,876 shares of United Therapeutics common stock.